A multidisciplinary approach to optimizing care of patients treated with alpelisib - ScienceDirect
Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2–Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations - Clinical Breast Cancer
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Pa | TCRM
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications | Breast Cancer Research | Full Text
Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance - Journal of Lipid Research
Hyperinsulinaemia in cancer | Nature Reviews Cancer
Cancers | Free Full-Text | Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer | HTML
Cancers | Free Full-Text | Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer | HTML
SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report | Clinical Diabetes and Endocrinology | Full Text
Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer - Cancer Treatment Reviews
Cancers | Free Full-Text | Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity | HTML
The mechanistic basis of PI3K inhibitor-associated hyperglycemia [5,... | Download Scientific Diagram
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations | Future Oncology
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations | Future Oncology
Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance - Journal of Lipid Research
Frontiers | Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations | Endocrinology
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management
Alpelisib Is Changing the Clinical Landscape in Breast Cancer Treatment
Targeting the PI3K/Akt/mTOR pathway. Akti, capivasertib, ipatasertib;... | Download Scientific Diagram
Patient With a PIK3CA-Positive Tumors Exhibits Hyperglycemia Associated With Alpelisib
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors | Nature Cancer
Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors - Ando - 2019 - Cancer Science - Wiley Online Library
The PI3K signaling pathway and inhibitors under development and/or... | Download Scientific Diagram
OncoPrescribe - Write The Perfect Prescription
Pharmacist Management of Alpelisib-Associated Hyperglycemia
